El Período de Tratamiento consta de las siguientes fases:

*Fase Neoadyuvante (Prequirúrgica): máximo de 8 ciclos

Ciclos 1 a 4 de paclitaxel (PTX) (1 ciclo = cada 3 semanas [Q3W]): nivolumab o placebo de nivolumab + paclitaxel semanalmente.

Seguido de ciclos 1 a 4 de antraciclina-ciclofosfamida (AC) (1 ciclo = cada 2 semanas [Q2W] o Q3W [la frecuencia de la dosis la determinará el Investigador]): nivolumab o placebo de nivolumab + AC



*Fase Adyuvante (Posquirúrgica): máximo de 7 ciclos. Ciclos 1 a 7 adyuvantes (1 ciclo = cada 4 semanas [Q4W]): nivolumab o placebo de nivolumab + ET.

MK-3475-756 (MSD)

This is your About page. This space is a great opportunity to give a full background on who you are, what you do and what your site has to offer. Your users are genuinely interested in learning more about you, so don’t be afraid to share personal anecdotes to create a more friendly quality.

Every website has a story, and your visitors want to hear yours. This space is a great opportunity to provide any personal details you want to share with your followers. Include interesting anecdotes and facts to keep readers engaged.


Double click on the text box to start editing your content and make sure to add all the relevant details you want site visitors to know. If you’re a business, talk about how you started and share your professional journey. Explain your core values, your commitment to customers and how you stand out from the crowd. Add a photo, gallery or video for even more engagement.



- Carcinoma ductal de mama invasivo localizado, confirmado por el patólogo local, que incluye T1c-T2 (tamaño del tumor ≥ 2 cm), estadio ganglionar clínico (cN) 1-cN2 o T3-T4, cN0-cN2. El estado ganglionar debe ser confirmado citológicamente. Nota: Se permite el BC inflamatorio.

-Los participantes deben tener BC ER+, HER2-

-Los participantes deben considerarse elegibles para quimioterapia neoadyuvante. 

-Los participantes deben considerarse elegibles para cirugía y deben aceptar someterse a cirugía después de completar la terapia neoadyuvante.

-Los participantes deben aceptar proporcionar tejido de tumor de mama primario en condición basal.